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ABSTRACT 
The objective of this study is to investigate the alcoholic extract of Leucas cephalotes for antidiabetic effects in laboratory animals. 
Diabetes was induced in rats by administration of alloxan (120 mg/kg body wt.). In normal rats, alcoholic extract had significantly 
decreased the blood glucose level (BGL) in a dose-dependent fashion after repeated administration of alcoholic extract for 7 days. In 
alloxan-induced diabetic rats, the extract decreased the BGL with significant improvement in glucose tolerance and body weight at 
the end of I, II and III week after alcoholic extract treatment. These results suggest that alcoholic extract is having potent antidiabetic 
activity in comparison with normal as well in diabetic rats. 
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INTRODUCTION 
The use of herbal drugs, extracts and plant based 
remedies has increased the ‘green’ revolution as herbal 
medicine is gaining popularity. Crude drugs which are 
obtained from the plant in the Core subject matter of 
Pharmacognosy are not only used for the treatment of 
various ailments but also in cosmetics, food and drug 
industries.The plants, are regaining the rightful place in 
treatment disease. Today’s applied science of 
Pharmacognosy has a far better knowledge of the active 
ingredients and their prominent therapeutic activity on 
the human beings. Medicinal plants are of great value 
for treatment and cure of ailments since ancient times, 
however scientific research has expanded our 
knowledge of the chemical effects and composition of 
the active constituents, which is responsible for 
medicinal properties. It is universal fact that the plant 
based drugs and treatments are far safer than synthetic 
medicines to cure the complex diseases like Cancer and 
AIDS
1
. 
Diabetes Mellitus (DM) is a chronic metabolic disorder 
characterized by a high blood glucose concentration- 
Hyperglycemia (fasting plasma glucose > 7.0 m mol/l, 
or plasma glucose > 10 m mol/l, 2 h after meal) due to 
Insulin deficiency and for insulin resistance. 
Hyperglycemia occurs due to hepatic glucose output and 
diminished uptake of glucose by skeletal muscle with 
reduced glycogen synthesis when the renal threshold for 
glucose reabsorption is exceeded, glucose spills over 
into the urine (glycosuria) and causes an osmotic 
diuresis (Polyuria) which in turn results in dehydration, 
thirst and increased drinking (Polydipsia).Low 
concentration of insulin causes wasting due to increased 
breakdown and reduced synthesis of proteins. The 
consequences of ketosis may occur in the absence of 
insulin as there is fast fat breakdown to Acetyl-COA. In 
the absence of aerobic carbohydrate metabolism, 
Acetyl-COA is converted anaerobically to acetoacetate 
etc
2
. 
As a consequence of the metabolic derangements in 
DM, various complications may grow in body system. 
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Many of these bad complications are due to diseases of 
blood vessels, improper functioning  of the vascular 
endothelium and abnormalities of endothelium-derived 
mediators,  RDS, protein kinase and non-enzymatic 
products of glucose and albumin have been implicated 
in these changes.  
Diabetic neuropathy is considered as one of the disease, 
associated with accumulation of poorly metabolized 
osmotically active metabolites of glucose including 
sorbitol, produced by the action of aldose reductase
3
  
There are two main forms of DM, 
 Type I diabetes (also known as Insulin-dependent 
diabetes mellitus- IDDM- or Juvenile onset 
diabetes). Another type IIdiabeties 
 Type II diabetes (also known as Non- Insulin- 
dependent diabetes mellitus- NIDDM- or maturity 
onset diabetes. 
In type I diabetes the absolute deficiency of insulin due 
to autoimmune destruction of β cells of langarhans 
occurs and due this, patient suffers from diabetic 
Ketoacidosis.  Patients of type IDM are usually young. 
In type II diabetes, chances of insulin resistance and 
impaired regulation of Insulin secretions observed. Such 
patients are usually obese, adult and aged. Treatment of 
such DM cases initially stats with oral hypoglycemic 
drugs or Insulin often become necessary
4
. 
 The plant (Leucas cephalotes SPRENG) is distributed 
in Punjab, Bengal, Assam, Himalaya, Rajputana Desert, 
Gujarat and also in Afghanistan.  It is an erect, 
scaberulous or pubescent, stout annual, 30-100 cm high 
found as a common weed in cultivated grounds and 
waste lands throughout the greater part of India 
ascending upto 1800 m in the Himalayas, leaves shortly 
petiolated narrowly ovate or ovate lanceolate, Crenate 
serrate. Flowers are small, white in dense terminal 
globose whorls, nutlets small, smooth brown
5
.  
The plant has a pungent taste with a flavour. It is 
Laxative, anthelmintic, stimulant, Diaphoretic useful in 
bronchitis, jaundice, inflammation, Asthma, Dyspepsia, 
paralysis, Leucoma. The leaves are also useful in Fevers 
and urinary discharges. The fruit juice in certain 
localities can be applicable as an external application in 
scabies. The flowers are administered in the form of 
syrup as domestic remedy for coughs and colds. The 
leaves are used combination with other drugs are to treat 
scorpion bite but they are not being used to prepare the 
chemical constituent antidote to scorpion venom. The 
plant is also used in piles and malaria
6
. 
From the whole herb of Leucas cephalotes Spreng, new 
Labdane, norlabdane and abietane- type diterpenes 
named Leucasdins A(1), B(2) and C(3), respectively, 
and two protostane- type triterpenes named Leucastrins 
A(4) and B(5) were isolated, together with a known 
triterpene, oleanolic acid, five sterols, 7-oxositosterol, 7- 
oxostigmosterol, 7 alpha- hydroxysitosterol, 7- alpha-
hydroxystigmesterol and stigmesterol, and eight 
flavones, 5- hydroxyl- 7,4- dimethoxyflavone, pilloin, 
gonzolitosin, tricin, cosmosin, apigenin 7-0-beta-D-(6-0-
P-coumaroyl) glucopyranoside, Anisofolin A and 
Luteolin 4-0-beta- D-glucuronopyranoside were 
isolated. 
2. MATERIALS AND METHODS 
Materials      
2.1 Plant material 
Whole plant of Leucas cephalotes were collected from 
Moradabad, U.P. and   the plant samples were 
authenticated by Dr. Ashok Kumar, Botanist, IFTM 
University, Moradabad. 
2.2 Laboratory Animals 
Albino rats of either sex weighing between 150-200gm 
were employed for this investigation. All the protocols 
related with animal experiment were approved by 
Institutional Animal ethics committee (IAEC).   All the 
chemicals were of AR grade and procured from CDH 
(P) Ltd, New Delhi. 
2.3 preparation of extract: 
Leucas cephalotes plants 
↓ 
Collected  
↓ 
Authenticated by taxonomist 
↓ 
Drying 
↓ 
Subjected to powdering 
↓ 
Subjected to suitable method of extraction 
Flow Chart showing Solvent extraction method 
The powder drug was extracted by the soxhlet extractor 
with successively different solvent, in increasing order 
of polarity. 
2.4 Preliminary phytochemical analysis: 
Extract was subjected to preliminary phytochemical 
investigation for detection of Triterpenes/ steroids, 
Flavonoids, Saponins, Reducing sugars and alkaloids. 
2.5. Determination of acute toxicity: (OECD, 2001) 
The acute toxicity of alcoholic extracts of Leucas 
cephalotes were determined by using female albino 
Wistar rats (150– 200 g), were maintained under the 
standard laboratory conditions. The animals (n = 6) were 
fasted 12 h before the experiment, up and down 
procedures were adopted for toxicity studies. Animals 
were administered with single dose of extract of Leucas 
cephalotes at a dose of 2000 mg/kg and observed for 
their mortality during 2 and 7 days study period (short 
term) toxicity and the dose increased up to 5000 mg/kg 
b.w. and were observed up to 7 days for their 
behavioral, economical and neurological profiles except 
slight depression in their activity. 
2.6. Assessments of anti-diabetic activity in alloxan-
induced diabetic rats: 
Alloxan monohydrate was dissolved in normal saline 
and administered i.v into fasted rats at a dose of 120 
mg/kg b.w. The freshly prepared solution was used for 
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administration. The rats were given 5% (w/v) glucose 
solution in feeding bottles for next 24 h in their cages to 
prevent hypoglycaemia after alloxan injection. After 72 
h rats with BGL greater than 200 mg/dl and less than 
400 mg/dl were selected and observed for 
hyperglycaemia (fasting blood glucose level –FBG) 
greater than 200 mg/dl and lesser then 400 mg/dl) up to 
7 days. Such animals were divided into six groups as 
follows:  
Group 1: Normal control (distilled water 10 ml/kg, p.o.) 
Group 2: Control (Alloxan treated with 120 mg/kg, p.o.) 
Group 3: Standard group (Glibenclamide 10 mg/kg, 
p.o.) 
Group 4: Low dose (100 mg/kg, p.o.) 
Group 5: Medium dose group (200 mg/kg, p.o.) 
Group 6: High dose group (400 mg/kg, p.o.) 
The treatment was continued for the next 21 days and 
blood samples were collected on 0
th
, 7
th
, 14
th
 and 21
st
 
days after 1 h administration. BGL was estimated at 
various time intervals GOD/P.O.D. kit. Serum test was 
carried out on day 21th was carried out. 
3. RESULT AND DISCUSSION 
3.1. Preliminary phytochemical analysis of Leucas 
cephalotes 
Phytochemical investigation of Leucas cephalotes 
revealed that ethanolic extract (EE) contains 
phytosterols, fixed oils, alkaloids, flavonoids, saponins, 
phytosterols and phenolics. 
The percentage yield of EE was 4.88%.  
3.2. Hypoglycaemic activity in normal rats 
Fasting blood glucose (FBG) levels were found within 
the range of 95–105 mg/dl in all the groups at 0 h. 
Single dose administration of EE (100, 200 and 400 
mg/kg) did not decreased the FBG level at various time 
intervals viz. 1, 2 and 4 h after treatment, indicating that 
the extracts could not produce significant 
hypoglycaemic activity after acute treatment (Table 1). 
Repeated administration of EE had significantly reduced 
the FBG on 7
th
 day, 14
th
 day and 21
st
 day with 400 
mg/kg and on 7
th
 day, indicating that the EE is effective 
in treating DM in long term therapy. (Figure 1). 
Glibenclamide (5 mg/kg) significantly reduced blood 
glucose level after single dose and repeated dose 
administration as compared to control groups. Fasting 
blood glucose (FBG) levels in normal rats were in the 
range of 95–100 mg/dl. Treatment with alloxan (120 
mg/kg, i.v.) had increased the blood glucose level 
(BGL) to a range of 250–270 mg/dl after 7 days. Single 
dose administration of EE (100, 200 and 400 mg/kg) did 
not significantly reduced the BGL in alloxan-induced 
diabetic rats, while Glibenclamide (5 mg/kg) 
significantly reduce the BGL at 1
st
 h of 1
st
 day 
treatment.
 
Table 1: BGL after 0
th, 
7
th
, 14
th
 and 21
th 
day 
Treatment Dose 0
th
 day 7
th
 day 14
th
 day 21
th
 day 
Normal 
control 
Blank 95.167±0.749 93.500±0.428 93.833±0.477 94.500±0.500 
Control (3% 
v/v tween 80) 
10 ml/kg 241.00±2.556 255.167±0.401 258.667±0.333 265.167±0.401 
Glibenclamide 10 mg/kg 231.33±0.558**** 107.833±0.401**** 94.333±0.333**** 87.833±0.307**** 
EE  100 mg/kg 237.33±0.760 235.167±0.477**** 191.500±0.224**** 178.833±0.307**** 
EE  200 mg/kg 238.667±0.558 208.667±0.919**** 186.667±0.333**** 163.33±0.333**** 
EE  400 mg/kg 233.667±0.211**** 201.833±1.922**** 141.167±0.477**** 102.167±0.872**** 
 
Figure 1: Glucose range in different treatment groups 
Islam et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(3):109-115 
ISSN: 2250-1177                                                                            [112]                                                                              CODEN (USA): JDDTAO 
3.3 Level of Urea, Creatinine, Total Protein, Serum 
albumin in animals 
Level of Urea, Creatinine, Total Protein, Serum albumin, 
A/G ration was measured after 7
th
 day of administering 
the Alloxan and start of treatment in animals. After 
administering the Alloxan at a single dose of (120 
mg/kg, i.v.) the level of Urea, Creatinine, Serum 
albumin was incresed in comparison to normal control 
but the level of total protein was reduced significantly. 
The standard Glibenclamide had reduced the level of 
Urea, Creatinine, albumin:globulin ration. The total 
protein and serum albumin was increased significantly in 
Glibenclamide treated group (control group). (Table 2) 
The findings suggested that EE in dose dependent 
fashion increased the concentration of total protein and 
serum albumin. The EE in dose dependent fashion 
reduced the level of urea leel, creatinine level and A/G 
ratio (Fig 2-9). 
 
Table 2: Level of urea, creatinine, total protein,Serum Albuminin animals 
Treatment Urea Level Creatinine 
Level 
Total Protein Serum 
Albumin 
A/G ratio 
Normal control 30.950±0.675 0.76±0.01 6.42±0.12 4.30±0.01 1.95±0.01 
Control  
(3% v/v tween 80) 
84.435±1.330 2.02±0.04 2.59±0.18 1.86±0.02 3.66±0.14 
Glibenclamide 45.290±1.713**** 0.98±0.01**** 6.06±0.02**** 3.78±0.06**** 2.06±0.2**** 
EE (100mg/kg b.w.) 80.905±0.320** 1.71±0.01*** 3.18±0.01*** 1.48±0.07** 3.10±0.05*** 
EE (200mg/kg b.w.) 71.640±0.523**** 1.58±0.02**** 4.19±0.01**** 2.27±0.11** 2.81±0.05**** 
EE (400mg/kg b.w.) 48.980±0.233**** 1.01±0.08**** 6.46±0.02**** 3.12±0.04**** 2.13±0.03**** 
 
Statistical analysis: 
Data were expressed as mean±SEM. Significance was calculated using one way ANOVA followed by Dunnet’s 
multiple comparison tests compared to control. 
 
Figure 2: Blood glucose range in different treatment group on 7th day. 
 
Figure 3: Blood glucose level range in different treatment groups on 14
th
day. 
Islam et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(3):109-115 
ISSN: 2250-1177                                                                            [113]                                                                              CODEN (USA): JDDTAO 
 
Figure 4: Blood glucose level range in different treatment groups on 21
st
 day. 
 
 
Figure 5: Urea level in treatment group. 
 
 
Figure 6: Total creatinine level in different treatment group. 
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Figure 7: Total protein level in different treatment groups. 
 
Figure 8: Total serum albumin level in different treatment groups. 
 
Figure 9: A/G Ratio level in different treatment groups. 
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The observation suggested that EE in 400mg/kg b.w. 
dose is highly efficient in maintaining all the 
biochemical parameters in laboratory animals. 
4. DISCUSSION 
The present study was aimed at discovering the 
antidiabetic properties of Leucas cephalotes in alloxan 
induced diabetes. In the traditional days Leucas 
cephalotes was used alone or in with other remedial 
measures against DM
7
. Alloxan causes a massive 
reduction in insulin release by the destruction of the β-
cells of the islets of langerhans, inducing 
hyperglycaemia. The rats (induced by alloxan) showed a 
persistent rise in BGL after 7
th
, 14
th
 and 21th day with 
the symptomatic features of DM
8
. The extract of Leucas 
cephalotes was not able to decrease the BGL in alloxan-
induced diabetic rats, on single dose administration 
which concludes that the extracts are ineffective
9
-
11
. The 
significant activity was attained on repeated 
administration of the EE from day 7
th
 by controlling the 
increased BGL compared with other group. The EE on 
repeated administration reduced the glucose level in 
diabetic rats on 7
th
, 14
th
 and 21
nd
 days as compared to 
diabetic control.  
While in case of EE (400 mg/kg) it has shown a 
significant reduction in blood glucose level on 7
th
 day, 
14
th
 day and 21
st
 day. 
CONCLUSION 
In conclusion, EE had shown a significant 
hypoglycaemic activity in normal rats, against alloxan 
induced rats. Ethanolic extract of   Leucas cephalotes 
exhibited antidiabetic potential on 0, 7, 14 and 21st day 
of treatment. 
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